Management of Hospitalized Respiratory Syncytial Virus Bronchiolitis in the Pediatric Ward in Spain: Assessing the Impact of a New Clinical Practice Protocol

2021 ◽  
Author(s):  
Jorgina Vila ◽  
Esther Lera ◽  
Paula Peremiquel-Trillas ◽  
Laia Martínez ◽  
Irene Barceló ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Respiratory Syncytial Virus ◽  
Pediatric Ward ◽  
Respiratory Syncytial Virus Bronchiolitis ◽  
Syncytial Virus ◽  
The Impact

scholarly journals Respiratory syncytial virus infection is an underestimated cause of viral pneumoniae in adults

2021 ◽  
Author(s):  
Lorenz Schubert ◽  
Johanna Steininger ◽  
Felix Lötsch ◽  
Anna Nele Herdina ◽  
Redlberger-Fritz Monika ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Respiratory Syncytial Virus ◽  
Virus Infection ◽  
Chronic Diseases ◽  
Respiratory Disease ◽  
Detection Rate ◽  
Correct Diagnosis ◽  
Advanced Age ◽  
Syncytial Virus ◽  
The Impact

Abstract Respiratory syncytial virus (RSV) testing is generally available in most care centres, but it is rarely performed because clinicians’ seldom suspect RSV to be the underlying pathogen in adults with respiratory disease. Here, we evaluate the impact of broad combined influenza/RSV testing on the clinical practice. Overall, 103 patients were tested positively for RSV. Our study indicates that positively tested patients were mostly of advanced age and suffered from chronic diseases. Mortality was significant in our cohort and higher in patients with advanced age. Further, we report a significant increase in detected RSV cases but also in detection rate. Together, these findings suggest that implementation of a combined influenza/RSV testing led to a significant increase in detection rate, supported clinicians establishing the correct diagnosis and allowed a safe and controlled handling of RSV patients.

scholarly journals Evaluating the Impact of Implementing a Clinical Practice Guideline for Febrile Infants With Positive Respiratory Syncytial Virus or Enterovirus Testing

2017 ◽  
pp. hpeds.2016-0217 ◽  
Author(s):  
Adrienne DePorre ◽  
David D. Williams ◽  
Jennifer Schuster ◽  
Jason Newland ◽  
Jacqueline Bartlett ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Respiratory Syncytial Virus ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Syncytial Virus ◽  
The Impact

scholarly journals Surveillance of respiratory syncytial virus infections in adults, Austria, 2017 to 2019

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lorenz Schubert ◽  
Johanna Steininger ◽  
Felix Lötsch ◽  
Anna Nele Herdina ◽  
Monika Redlberger-Fritz ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Respiratory Syncytial Virus ◽  
Chronic Diseases ◽  
Respiratory Disease ◽  
Detection Rate ◽  
Correct Diagnosis ◽  
Advanced Age ◽  
Virus Infections ◽  
Syncytial Virus ◽  
The Impact

AbstractRespiratory syncytial virus (RSV) testing is generally available in most care centres, but it is rarely performed because clinicians’ seldom suspect RSV to be the underlying pathogen in adults with respiratory disease. Here, we evaluate the impact of broad combined influenza/RSV testing on the clinical practice. Overall, 103 patients were tested positively for RSV. Our study indicates that positively tested patients were mostly of advanced age and suffered from chronic diseases. Mortality was significant in our cohort and higher in patients with advanced age. Further, we report a significant increase in detected RSV cases but also in detection rate. Together, these findings suggest that implementation of a combined influenza/RSV testing led to a significant increase in detection rate, supported clinicians establishing the correct diagnosis and allowed a safe and controlled handling of RSV patients.

scholarly journals 1719. Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S843-S843
Author(s):  
John M McLaughlin ◽  
Farid L Khan ◽  
Heinz-Josef Schmitt ◽  
Yasmeen Agosti ◽  
Luis Jodar ◽  
...  
Keyword(s):  
Public Health ◽  
Respiratory Syncytial Virus ◽  
Active Surveillance ◽  
Meta Analysis ◽  
The United States ◽  
Administrative Claims ◽  
Prevention Strategies ◽  
Hospitalization Rates ◽  
Syncytial Virus ◽  
The Impact

Abstract Background Understanding the true magnitude of infant respiratory syncytial virus (RSV) burden is critical for determining the potential public-health benefit of RSV prevention strategies. Although global reviews of infant RSV burden exist, none have summarized data from the United States or evaluated how RSV burden estimates are influenced by variations in study design. Methods We performed a systematic literature review and meta-analysis of studies describing RSV-associated hospitalization rates among US infants. We also examined the impact of key study characteristics on these estimates. Results After review of 3058 articles through January 2020, we identified 25 studies with 31 unique estimates of RSV-associated hospitalization rates. Among US infants < 1 year of age, annual rates ranged from 8.4 to 40.8 per 1000 with a pooled rate= 19.4 (95%CI= 17.9–20.9). Study type was associated with RSV hospitalization rates (P =.003), with active surveillance studies having pooled rates per 1000 (11.1; 95%CI: 9.8–12.3) that were half that of studies based on administrative claims (21.4; 95%CI: 19.5–23.3) or modeling approaches (23.2; 95%CI: 20.2–26.2). Conclusion Applying the pooled rates identified in our review to the 2020 US birth cohort suggests that 73,680 to 86,020 RSV-associated infant hospitalizations occur each year. To date, public-health officials have used conservative estimates from active surveillance as the basis for defining US infant RSV burden. The full range of RSV-associated hospitalization rates identified in our review better characterizes the true RSV burden in infants and can better inform future evaluations of RSV prevention strategies. Disclosures John M. McLaughlin, PhD, Pfizer (Employee, Shareholder) Farid L. Khan, MPH, Pfizer (Employee, Shareholder) Heinz-Josef Schmitt, MD, Pfizer (Employee, Shareholder) Yasmeen Agosti, MD, Pfizer (Employee, Shareholder) Luis Jodar, PhD, Pfizer (Employee, Shareholder) Eric Simões, MD, Pfizer (Consultant, Research Grant or Support) David L. Swerdlow, MD, Pfizer (Employee, Shareholder)

Sign in / Sign up

Export Citation Format

Share Document